hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration

Table 2

Association between the expression of TSPAN9 and clinicopathological features of HCC patients.

Variables	Total	TSPAN9 staining
		Positive	Negative
Age
<50	37	32	5	4.065	0.044
≥50	53	36	17
Gender
Male	10	6	4	1.474	0.225
Female	80	62	18
Recurrence
No	41	36	5	6.118	0.013
Yes	49	32	17
Tumor size
<5	55	46	9	5.000	0.025
≥5	13	22	35
Pathological grade
I+II	43	33	10	0.063	0.802
III	12	35	47
Number of tumors
<2	79	60	19	0.054	0.816
≥2	11	8	3
Cirrhotic nodules
<3	56	42	14	0.025	0.875
≥3	34	26	8
Tumor capsule
Complete	43	34	9	0.551	0.458
Incomplete	47	34	13
Clinical stage
I	63	50	13	1.650	0.199
II+III	27	18	9
Total bilirubin (μmol/L)
<17	65	47	18	2.244	0.134
≥17	24	21	3
Hepatitis B virus
Positive	19	13	6	0.854	0.355
Negative	70	55	15
Serum AFP (ng/mL)
<25	37	31	6	2.303	0.129
≥25	53	37	16
ALT (ng/mL)
<40	52	36	16	2.668	0.102
≥40	38	32	6
GGT (U/L)
<50	45	36	9	0.963	0.327
≥50	45	32	13

Notes: bold values indicate significance.